Identification of a Plasma Proteomic Signature for Lung Cancer

Status Completed

Clinical Trial Summary

The primary objective is to identify a panel of plasma and/or serum proteins that differentiates the absence or presence of lung malignancy in samples obtained from subjects enrolled in this IRB/EC approved study with pulmonary nodules.

Clinical Trial Description

Blood samples are obtained from those patients undergoing procedures to determine if a lung nodule is benign or cancerous. The data from the study will not be used to guide or influence the treatment of the patients enrolled in this study. There is no change from the normal standard of care that patients receive. ;

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01752101
Study type	Observational
Source	Integrated Diagnostics
Contact
Status	Completed
Phase	N/A
Start date	October 2012
Completion date	December 2014

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05283226` - Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor Therapy	Phase 2
Active, not recruiting	`NCT04362072` - Study of Lorlatinib In People With ALK-positive Non-small Cell Lung Cancer	Phase 4
Completed	`NCT04033991` - Study of Patients With Metastatic and/or Advanced Renal Cell Carcinoma, Treated With Sunitinib/Axitinib.
Recruiting	`NCT02292641` - Beyond TME Origins	N/A
Not yet recruiting	`NCT02907606` - Urinary Circulating Tumor DNA Detection in Non-small Cell Lung Cancer: a Prospective Study	N/A
Completed	`NCT02507544` - A Safety and Pharmacokinetic Study of TRX-818 Administered Orally to Patients With Advanced Cancer	Phase 1
Completed	`NCT01942200` - A Non Interventional Study With Oxaliplatin Onkovis (Oxaliplatin) Utilized for the Treatment of Cancer
Completed	`NCT01061645` - Study of MOC31-PE in Antigen Positive Carcinomas	Phase 1
Terminated	`NCT00557596` - A Phase 1-2, XIAP Antisense AEG35156 With Gemcitabine in Patients With Advanced Pancreatic Cancer	Phase 1/Phase 2
Completed	`NCT00532155` - A Study of Aflibercept Versus Placebo in Patients With Second-Line Docetaxel for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer	Phase 3
Completed	`NCT00216372` - Efficacy and Safety of Lanreotide Microparticles as Palliative Treatment in Peritoneal Carcinomatosis	Phase 3
Recruiting	`NCT06022757` - Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19)	Phase 1/Phase 2
Recruiting	`NCT05520281` - Short-term Psychodynamic Psychotherapy in Serious Physical Illness	N/A
Recruiting	`NCT05752357` - The Role of Pre-operative and Post-operative Circulating Tumor Cells in Gastric Cancer.
Not yet recruiting	`NCT05023928` - Tumor Antigen-sensitized DC Vaccine as an Adjuvant Therapy for Esophagus Cancer	Phase 1
Completed	`NCT00446446` - PRISM (Panitumumab Regimen In Second-line Monotherapy of Head and Neck Cancer)	Phase 2
Recruiting	`NCT04566952` - Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian Cancer	Phase 2
Not yet recruiting	`NCT06112041` - The Prospective Clinical Study of Precision PRaG Therapy in Elderly Patients With Advanced Solid Malignant Tumors (PRaG9.0)	Phase 2
Completed	`NCT03562897` - Evaluation of Ocoxin-Viusid® in Advanced or Metastatic Ovarian Epithelial Cancer	Phase 2
Recruiting	`NCT06013111` - An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti-CEA-CAR-T Cells Injection in Patients With CEA+ Locally Advanced and/or Metastatic Solid Tumors	Phase 1